GeneDx names former Quest executive Mark Gardner as president
PUBT · 3d ago
Share
Listen to the news
- GeneDx appointed Mark Gardner as president, effective June 15, 2026.
- He will run commercial operations, aiming to tighten execution, scale the business, expand its position in genomic medicine.
- Gardner previously led molecular genomics and oncology as senior vice president at Quest Diagnostics.
- He was CEO of OmniSeq before its acquisition by Labcorp.
- Earlier roles included senior leadership posts at Thermo Fisher Scientific, Life Technologies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606160830BIZWIRE_USPR_____20260616_BW791724) on June 16, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved